\Acacatm1Dejs/\Acacatm1Dejs
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * DBA/2
|
increased T cell proliferation |
J:209886
|
\Airetm1.1Doi/\Airetm1.1Doi
\Tg(Ins2-TFRC/OVA)296Wehi/0
\Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell differentiation |
J:135154
|
|
decreased CD4-positive, alpha-beta T cell number |
J:135154
|
\Airetm1Mand/\Aire+
\Tg(Ins2-TFRC/OVA)296Wehi/0
\Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell differentiation |
J:135154
|
\Airetm1Mmat/\Airetm2Mmat
\Tg(TcraTcrb)425Cbn/?
involves: BALB/c * C57BL/6 * CBA
|
abnormal thymus morphology |
J:141379
|
|
normal
immune system phenotype |
J:141379
|
\B2mtm1Unc/\B2mtm1Unc
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0
NOD.Cg-B2mtm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
abnormal CD8-positive, alpha beta T cell morphology |
J:93553
|
|
decreased susceptibility to autoimmune diabetes |
J:93553
|
\Bcl6tm1.1Toka/\Bcl6+
\Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6 * NZB
|
decreased T cell proliferation |
J:174014
|
\Bcl11btm1Avram/\Bcl11btm1Avram
\Tcratm1Mom/\Tcratm1Mom
\Tg(Cd4-cre)1Cwi/?
involves: 129 * C57BL/6 * DBA/2
|
abnormal positive T cell selection |
J:128515
|
|
decreased double-positive T cell number |
J:128515
|
|
thymus hypoplasia |
J:128515
|
\Brca1tm2Mak/\Brca1tm2Mak
\Tg(Lck-cre)548Jxm/?
\Tg(TcrLCMV)327Sdz/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal T cell number |
J:63282
|
|
decreased double-positive T cell number |
J:63282
|
|
decreased T cell proliferation |
J:63282
|
|
decreased thymocyte number |
J:63282
|
|
increased double-negative T cell number |
J:63282
|
\Btlatm1Dgra/\Btlatm1Dgra
\Tg(TcraTcrb)425Cbn/?
involves: C57BL/6
|
abnormal peripheral T cell anergy |
J:147751
|
\Btlatm1Dgra/\Btlatm1Dgra
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal peripheral T cell anergy |
J:147751
|
\Btlatm1Kmm/\Btlatm1Kmm
\Tg(DO11.10)10Dlo/?
involves: 129S/SvEv * BALB/c * C3H * C57BL/6
|
increased T cell proliferation |
J:84084
|
\Camltm1Rjb/\Camltm2Rjb
\Tg(Lck-cre)1Cwi/0
\Tg(TcraTcrb)1100Mjb/0
involves: 129 * C57BL/6 * DBA/2
|
abnormal negative T cell selection |
J:100536
|
|
abnormal positive T cell selection |
J:100536
|
|
decreased thymocyte number |
J:100536
|
\Card11tm1.1Litt/\Card11tm1.1Litt
\Gt(ROSA)26Sortm1(cre/ERT2)Thl/\Gt(ROSA)26Sor+
\Tg(TcraTcrb)425Cbn/?
involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal T cell activation |
J:180410
|
\Casp3tm1Mak/\Casp3tm1Mak
\Tg(TcrLCMV)327Sdz/0
B6.Cg-Casp3tm1Mak Tg(TcrLCMV)327Sdz
|
abnormal CD8-positive, alpha beta T cell morphology |
J:97650
|
|
decreased cell proliferation |
J:97650
|
|
decreased physiological sensitivity to xenobiotic |
J:97650
|
\Ccr7tm1Rfor/\Ccr7tm1Rfor
\Tg(DO11.10)10Dlo/?
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
abnormal cell migration |
J:123482
|
|
abnormal leukocyte migration |
J:123482
|
|
abnormal regulatory T cell physiology |
J:123482
|
\Cd3etm1.1Geno/\Cd3etm1.1Geno
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:192604
|
|
abnormal positive T cell selection |
J:192604
|
|
increased DN3 thymocyte number |
J:192604
|
\Cd3etm1.1Geno/\Cd3etm1.1Geno
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
abnormal CD4-positive T cell differentiation |
J:192604
|
|
abnormal positive T cell selection |
J:192604
|
|
increased DN3 thymocyte number |
J:192604
|
\Cd3etm1.1Geno/\Cd3etm1.1Geno
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
abnormal positive T cell selection |
J:192604
|
|
abnormal T cell differentiation |
J:192604
|
|
abnormal thymus cell ratio |
J:192604
|
|
decreased double-positive T cell number |
J:192604
|
|
decreased T cell number |
J:192604
|
|
increased DN3 thymocyte number |
J:192604
|
\Cd3gtm1.1Cage/\Cd3gtm1.1Cage
\Tg(TcrLCMV)318Sdz/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
abnormal response to infection |
J:142387
|
|
abnormal T cell physiology |
J:142387
|
|
normal
immune system phenotype |
J:142387
|
\Cd4tm1Jrp/\Cd4tm1Jrp
\Tg(TcrAND)53Hed/0
either: (involves: 129S2/SvPas * C57BL/6 * SJL) or (involves: 129S2/SvPas * C57BL/6 * C57BL/10 * SJL)
|
abnormal T cell number |
J:45168
|
|
thymus hyperplasia |
J:45168
|
\Cd4tm1Knw/\Cd4tm1Knw
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0
NOD.Cg-Cd4tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
increased susceptibility to autoimmune diabetes |
J:93553
|
\Cd5tm1.1Chra/\Cd5tm1.1Chra
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: C57BL/6 * FVB/N
|
decreased interferon-gamma secretion |
J:189919
|
|
decreased interleukin-2 secretion |
J:189919
|
|
decreased T cell proliferation |
J:189919
|
|
decreased T helper 1 cell number |
J:189919
|
|
increased interferon-gamma secretion |
J:189919
|
|
increased interleukin-6 secretion |
J:189919
|
|
increased interleukin-17 secretion |
J:189919
|
\Cd8atm1Asin/\Cd8atm1Asin
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J
|
abnormal CD8-positive, alpha beta T cell morphology |
J:125259
|
\Cd8atm1Asin/\Cd8atm1Asin
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N
|
abnormal positive T cell selection |
J:126026
|
|
decreased CD4-positive, alpha-beta T cell number |
J:126026
|
|
increased CD8-positive, alpha-beta T cell number |
J:126026
|
\Cd8b1tm1Litt/\Cd8b1+
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S4/SvJae * C57BL/6J * DBA/2
|
decreased double-positive T cell number |
J:112551
|
\Cd8b1tm1Litt/\Cd8b1tm1Litt
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S4/SvJae * C57BL/6J * DBA/2
|
abnormal lymph node cell ratio |
J:112551
|
|
abnormal negative T cell selection |
J:112551
|
|
abnormal positive T cell selection |
J:112551
|
|
decreased CD8-positive, alpha-beta T cell number |
J:112551
|
|
increased CD4-positive, alpha-beta T cell number |
J:112551
|
\Cd28tm1Mak/\Cd28tm1Mak
\Tg(TcrLCMV)327Sdz/0
involves: 129S2/SvPas * C57BL/6 * DBA/2
|
abnormal T cell anergy |
J:123989
|
|
decreased cytotoxic T cell cytolysis |
J:123989
|
|
decreased splenocyte proliferation |
J:123989
|
|
decreased T cell proliferation |
J:123989
|
\Cd28tm1Pjl/\Cd28tm1Pjl
\Tg(DO11.10)10Dlo/0
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
abnormal T cell activation |
J:25536
|
|
abnormal T cell proliferation |
J:25536
|
|
abnormal thymocyte activation |
J:25536
|
|
decreased interleukin-2 secretion |
J:25536
|
\Cd40lgtm1Flv/\Cd40lgtm1Flv
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo
involves: 129P2/OlaHsd * 129S2/SvPas * MRL
|
abnormal kidney morphology |
J:38492
|
|
decreased autoantibody level |
J:38492
|
|
increased anti-double stranded DNA antibody level |
J:38492
|
|
normal
integument phenotype |
J:38492
|
\Cd40lgtm1Flv/Y
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo
involves: 129P2/OlaHsd * 129S2/SvPas * MRL
|
abnormal kidney morphology |
J:38492
|
|
decreased autoantibody level |
J:38492
|
|
increased anti-double stranded DNA antibody level |
J:38492
|
|
normal
integument phenotype |
J:38492
|
\Cd84tm1Pls/\Cd84tm1Pls
\Tg(TcraTcrb)425Cbn/?
B6.Cg-Cd84tm1Pls Tg(TcraTcrb)425Cbn
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:157915
|
\Cd226tm1.1Cln/\Cd226tm1.1Cln
\Tg(TcraTcrb)1100Mjb/0
B6.Cg-Cd226tm1.1Cln Tg(TcraTcrb)1100Mjb
|
abnormal T cell activation |
J:159749
|
|
decreased cytotoxic T cell cytolysis |
J:159749
|
|
decreased interferon-gamma secretion |
J:159749
|
|
decreased T cell proliferation |
J:159749
|
\Cd247tm2.1Lov/\Cd247tm2.1Lov
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:192915
|
\Cd274tm1Shr/\Cd274tm1Shr
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
increased susceptibility to autoimmune diabetes |
J:153040
|
\Cops5tm1Rpar/\Cops5tm1Rpar
\Tg(Lck-cre)548Jxm/0
\Tg(TcraTcrb)425Cbn/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL
|
decreased thymocyte number |
J:132114
|
\Ctcftm2Gal/\Ctcftm2Gal
\Tg(Lck-cre)1Cwi/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * DBA/2J
|
abnormal T cell differentiation |
J:143271
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143271
|
|
decreased CD8-positive, alpha-beta T cell number |
J:143271
|
|
decreased double-positive T cell number |
J:143271
|
\Ctcftm2Gal/\Ctcftm2Gal
\Tg(Lck-cre)1Cwi/0
\Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell differentiation |
J:143271
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143271
|
|
decreased double-positive T cell number |
J:143271
|
|
decreased T cell number |
J:143271
|
|
increased double-negative T cell number |
J:143271
|
|
increased single-positive T cell number |
J:143271
|
\Ctla4tm1All/\Ctla4tm1All
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcrAND)53Hed/0
involves: 129S/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal T cell activation |
J:119845
|
|
increased interleukin-4 secretion |
J:119845
|
|
increased T cell proliferation |
J:119845
|
\Ctla4tm1All/\Ctla4tm1All
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraTcrb)8Rest/0
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:140448
|
|
normal
mortality/aging |
J:140448
|
|
normal
pigmentation phenotype |
J:140448
|
\Ctla4tm1All/\Ctla4tm1All
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD * SJL
|
abnormal splenocyte physiology |
J:109887
|
|
enlarged spleen |
J:109887
|
|
increased acute inflammation |
J:109887
|
|
insulitis |
J:109887
|
|
normal
mortality/aging |
J:109887
|
\Ctla4tm1All/\Ctla4tm1All
\Tg(TcrAND)53Hed/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal lymphopoiesis |
J:119845
|
|
abnormal T cell activation |
J:119845
|
|
abnormal T cell subpopulation ratio |
J:119845
|
|
increased CD4-positive, alpha-beta T cell number |
J:119845
|
|
increased CD8-positive, alpha-beta T cell number |
J:119845
|
|
premature death |
J:119845
|
\Ctla4tm1All/\Ctla4tm1All
\Tg(TcraTcrb)8Rest/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased CD8-positive, alpha-beta T cell number |
J:140448
|
|
increased CD4-positive, alpha-beta T cell number |
J:140448
|
|
increased interferon-gamma secretion |
J:140448
|
|
premature death |
J:140448
|
|
variable depigmentation |
J:140448
|
\Ctla4tm1Shr/\Ctla4tm1Shr
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(DO11.10)10Dlo/0
involves: 129S/Sv * BALB/c * C3H * C57BL/6
|
abnormal cytokine secretion |
J:110446
|
|
abnormal T cell physiology |
J:110446
|
|
normal
immune system phenotype |
J:110446
|
\Ctla4tm1Shr/\Ctla4tm1Shr
\Tg(DO11.10)10Dlo/0
involves: 129S4/SvJae * BALB/c * C3H * C57BL/6
|
abnormal T cell physiology |
J:57090
|
|
enlarged lymph nodes |
J:57090
|
|
enlarged spleen |
J:57090
|
|
increased T cell proliferation |
J:57090
|
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw
\TcraLn1Ogu/\Tcra+
involves: 129/Sv * C57BL/6
|
abnormal NK T cell morphology |
J:152041
|
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw
\Tg(TcraAV19AJ33)1Shima/0
involves: 129S4/SvJae * C57BL/6
|
abnormal NK T cell morphology |
J:112657
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:112657
|
|
increased interleukin-10 secretion |
J:112657
|
\Dock2tm1Tsas/\Dock2tm1Tsas
\Tg(Tcra2B4)1Mmd/?
\Tg(Tcrb2B4)1Mmd/?
involves: C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:84581
|
|
abnormal T cell physiology |
J:84581
|
|
decreased double-positive T cell number |
J:84581
|
\Dock8tm1Ysfk/\Dock8tm1Ysfk
\Il31tm1.1Ysfk/\Il31tm1.1Ysfk
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
\Dock8tm1Ysfk/\Dock8tm1Ysfk
\Osmrtm1Mtan/\Osmrtm1Mtan
\Tg(TcrAND)53Hed/0
involves: 129S/SvEv * C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
\Dock8tm1Ysfk/\Dock8tm1Ysfk
\Tac2em1Ysfk/\Tac2em1Ysfk
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
\Dock8tm1Ysfk/\Dock8tm1Ysfk
\Tac2em2Ysfk/\Tac2em2Ysfk
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
\Dock8tm1Ysfk/\Dock8tm1Ysfk
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
dermatitis |
J:305132
|
|
increased pruritus |
J:305132
|
\E2f2tm1Zubi/\E2f2tm1Zubi
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J
|
abnormal immune system morphology |
J:76318
|
|
abnormal immune system physiology |
J:76318
|
|
enlarged spleen |
J:76318
|
|
increased CD8-positive, alpha-beta T cell number |
J:76318
|
|
increased inflammatory response |
J:76318
|
|
increased susceptibility to autoimmune disorder |
J:76318
|
|
increased T cell proliferation |
J:76318
|
|
premature death |
J:76318
|
|
thymus hypoplasia |
J:76318
|
\Ebi3Gt716Lex/\Ebi3Gt716Lex
\Tg(DO11.10)10Dlo/0
involves: 129S5/SvEvBrd * BALB/c * C3H * C57BL/6
|
abnormal circulating interleukin level |
J:134148
|
|
abnormal T cell differentiation |
J:134148
|
|
decreased susceptibility to bacterial infection |
J:134148
|
|
increased circulating interleukin-17 level |
J:134148
|
|
increased interleukin-17 secretion |
J:134148
|
\Elavl1tm1Dkon/\Elavl1tm1Dkon
\Tg(Lck-cre)I57Jxm/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
B6.Cg-Elavl1tm1Dkon Tg(Lck-cre)I57Jxm Tg(TcraH-Y,TcrbH-Y)71Vbo
|
abnormal negative T cell selection |
J:148866
|
|
increased thymocyte number |
J:148866
|
\Elk4tm1Rtr/\Elk4tm1Rtr
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129/Sv * C57BL/6 * DBA/2J
|
abnormal positive T cell selection |
J:88515
|
|
decreased CD8-positive, alpha-beta T cell number |
J:88515
|
\Elk4tm1Rtr/\Elk4tm1Rtr
\Tg(TcraTcrb)425Cbn/?
involves: 129/Sv * C57BL/6
|
abnormal positive T cell selection |
J:88515
|
|
abnormal splenic cell ratio |
J:88515
|
|
decreased CD4-positive, alpha-beta T cell number |
J:88515
|
\Elk4tm1Rtr/\Elk4tm1Rtr
\Tg(TcrLCMV)327Sdz/?
involves: 129/Sv * C57BL/6 * DBA/2
|
abnormal positive T cell selection |
J:88515
|
|
decreased CD8-positive, alpha-beta T cell number |
J:88515
|
\Erap1tm1Luc/\Erap1tm1Luc
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcrLCMV)327Sdz/\Tg(TcrLCMV)327Sdz
involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * C57BL/10SgSnAi * DBA/2
|
normal
immune system phenotype |
J:122479
|
\Ets1tm1Jml/\Ets1tm1Jml
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S/SvEv * C57BL/6 * C57BL/6J * DBA/2J
|
decreased CD8-positive, alpha-beta T cell number |
J:125056
|
|
normal
immune system phenotype |
J:125056
|
|
increased double-negative T cell number |
J:125056
|
\Faddtm1Wnt/\Faddtm1Wnt
\Tg(Fadd)33Wnt/0
\Tg(Lck-cre)I57Jxm/0
\Tg(Tcra2C,Tcrb2C)1Dlo/0
involves: 129S4/SvJae * C57BL/6 * C57L * CBA * ICR * SJL
|
increased double-negative T cell number |
J:69617
|
|
thymus hypoplasia |
J:69617
|
\Faslpr/\Fas+
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * MRL/Mp
|
liver inflammation |
J:72817
|
|
normal
liver/biliary system phenotype |
J:72817
|
|
normal
mortality/aging |
J:72817
|
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcra+
MRL.Cg-Tcratm1Mjo Faslpr
|
normal
immune system phenotype |
J:108590
|
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo
involves: 129P2/OlaHsd * 129S2/SvPas * MRL
|
abnormal kidney morphology |
J:38492
|
|
decreased autoantibody level |
J:38492
|
|
decreased immunoglobulin level |
J:38492
|
|
extended life span |
J:38492
|
|
skin lesions |
J:38492
|
\Faslpr/\Faslpr
\Tcratm1Mjo/\Tcratm1Mjo
involves: 129P2/OlaHsd * MRL
|
abnormal kidney morphology |
J:45448
|
|
abnormal renal glomerulus morphology |
J:45448
|
|
normal
immune system phenotype |
J:26250
|
|
increased blood urea nitrogen level |
J:45448
|
|
increased gamma-delta intraepithelial T cell number |
J:26250
|
|
increased gamma-delta T cell number |
J:26250
|
|
increased T cell number |
J:26250
|
|
increased urine protein level |
J:45448
|
|
kidney inflammation |
J:45448
|
\Fastm1Vbo/\Fastm1Vbo
\Tg(Ins2-cre)25Mgn/0
\Tg(Ins2-HA)165Bri/0
\Tg(Tcra/Tcrb)1Vbo/0
Not Specified
|
increased susceptibility to autoimmune diabetes |
J:85985
|
\Fbn1Tsk/\Fbn1+
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/10 * DBA/2
|
emphysema |
J:57957
|
|
normal
integument phenotype |
J:57957
|
\Fbn1Tsk/\Fbn1+
\Tg(Tcra2C,Tcrb2C)1Dlo/?
involves: C57BL/10 * DBA/2
|
emphysema |
J:57957
|
|
normal
integument phenotype |
J:57957
|
\Foxo1tm1Flv/\Foxo1tm1Flv
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(CD2-Il7r)1Asin/?
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2
|
decreased T cell number |
J:147057
|
\Foxo1tm1Flv/\Foxo1tm1Flv
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2
|
decreased T cell number |
J:147057
|
\Foxp3tm1.1Ayr/Y
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraTcrb)425Cbn/0
Not Specified
|
normal
immune system phenotype |
J:97029
|
|
no abnormal phenotype detected |
J:97029
|
\Gata3tm1Iho/\Gata3tm1Iho
\Tg(Cd4-cre)1Cwi/0
\Tg(DO11.10)10Dlo/0
involves: BALB/c * C3H * C57BL/6 * DBA/2
|
decreased CD4-positive, alpha-beta T cell number |
J:86996
|
\Gata3tm1Iho/\Gata3tm1Iho
\Tg(DO11.10)10Dlo/0
\Tg(Lck-cre)1Cwi/0
involves: BALB/c * C3H * C57BL/6
|
arrested T cell differentiation |
J:86996
|
|
decreased CD4-positive, alpha-beta T cell number |
J:86996
|
|
decreased CD8-positive, alpha-beta T cell number |
J:86996
|
|
decreased double-positive T cell number |
J:86996
|
|
small thymus |
J:86996
|
\Gata3tm1Jfz/\Gata3tm1Jfz
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Cd4-cre)1Cwi/0
\Tg(Tcra5CC7,Tcrb5CC7)IWep/0
involves: 129S/SvEv * C57BL/6 * DBA/2
|
abnormal T cell differentiation |
J:141145
|
\Gimap5m1Btlr/\Gimap5m1Btlr
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6J * DBA/2J
|
decreased CD8-positive, alpha-beta T cell number |
J:160090
|
|
decreased thymocyte number |
J:160090
|
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
\Tg(DO11.10)10Dlo/0
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:160613
|
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6J * DBA/2J
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:160613
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:160613
|
|
abnormal cell migration |
J:160613
|
|
abnormal positive T cell selection |
J:160613
|
|
decreased CD8-positive, alpha-beta T cell number |
J:160613
|
\Git2Gt(XG510)Byg/\Git2Gt(XG510)Byg
\Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:160613
|
\Gpr15tm1.1Litt/\Gpr15tm1.1Litt
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6
|
abnormal immune system physiology |
J:199126
|
\Grb2tm1.1Hua/\Grb2tm1.1Hua
\Tg(DO11.10)10Dlo/0
\Tg(Lck-cre)1Jtak/0
involves: 129 * BALB/c * C3H * C57BL/6
|
abnormal T cell differentiation |
J:161294
|
|
decreased CD4-positive, alpha-beta T cell number |
J:161294
|
\Grb2tm1.1Hua/\Grb2tm1.1Hua
\Tg(Lck-cre)1Jtak/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:161294
|
|
decreased CD4-positive, alpha-beta T cell number |
J:161294
|
|
decreased CD8-positive, alpha-beta T cell number |
J:161294
|
|
increased CD8-positive, alpha-beta T cell number |
J:161294
|
|
increased double-positive T cell number |
J:161294
|
\Gt(ROSA)26Sortm1(HA)Libl/\Gt(ROSA)26Sortm1(HA)Libl
\Mogtm1(cre)Gkl/?
\Tg(TcraCl4,TcrbCl4)1Shrm/0
involves: 129/Sv * BALB/c * C57BL/6
|
abnormal oligodendrocyte morphology |
J:137838
|
|
abnormal optic nerve morphology |
J:137838
|
|
brain inflammation |
J:137838
|
|
decreased locomotor activity |
J:137838
|
|
demyelination |
J:137838
|
|
impaired righting response |
J:137838
|
|
optic nerve inflammation |
J:137838
|
|
spinal cord inflammation |
J:137838
|
|
tremors |
J:137838
|
|
weight loss |
J:137838
|
\Gt(ROSA)26Sortm2(OVA/EGFP)Dwir/\Gt(ROSA)26Sor+
\Tg(TcraTcrb)1100Mjb/0
\Albtm1(cre/ERT2)Mtz/\Alb+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased circulating alanine transaminase level |
J:173806
|
\H2-Kbm1/\H2-Kbm1
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal positive T cell selection |
J:92867
|
\H2-Kbm5/\H2-Kbm5
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal positive T cell selection |
J:133645
|
\H2-T18b/\H2-T18b
\H2-T3tm1Luc/\H2-T3tm1Luc
\Tcratm1Mom/\Tcratm1Mom
B6.Cg-Tcratm1Mom H2-T3tm1Luc
|
abnormal intraepithelial T cell number |
J:142515
|
|
colitis |
J:142515
|
|
enlarged mesenteric lymph nodes |
J:142515
|
|
increased interleukin-4 secretion |
J:142515
|
|
premature death |
J:142515
|
\H2-T23tm2Cant/\H2-T23tm2Cant
\Tg(Tcra2D2,Tcrb2D2)1Kuch/?
involves: 129S6/SvEvTac
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:142087
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:142087
|
\H2-T23tm3Cant/\H2-T23tm3Cant
\Tg(Tcra2D2,Tcrb2D2)1Kuch/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:142087
|
\H2-T23tm3Cant/\H2-T23tm3Cant
\Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:142087
|
\H2b/\H2b
\Itktm1Ljb/\Itktm1Ljb
\Tg(TcrAND)53Hed/?
involves: C3H/HeJ * C57BL/6 * C57BL/10
|
abnormal positive T cell selection |
J:123795
|
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
\H2b/\H2b
\Nfkbidtm1Clay/\Nfkbidtm1Clay
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraN15,TcrbN15)L2Elre/?
involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6
|
abnormal thymocyte activation |
J:132071
|
|
decreased interleukin-2 secretion |
J:132071
|
|
decreased T cell proliferation |
J:132071
|
\H2b/\H2b
\Ptcratm1Vbo/\Ptcratm1Vbo
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
|
decreased thymocyte number |
J:131357
|
\H2b/\H2b
\Ptcratm1Vbo/\Ptcratm1Vbo
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
\H2b/\H2b
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraN15,TcrbN15)L2Elre/?
involves: 129S/SvEv * C57BL/6
|
abnormal cytotoxic T cell physiology |
J:133112
|
|
arrested T cell differentiation |
J:133112
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133112
|
|
increased CD8-positive, alpha-beta T cell number |
J:133112
|
|
increased T cell proliferation |
J:133112
|
\H2b/\H2b
\Tcra/Tcrdtm1.1(Tcra)Rsky/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:81564
|
|
abnormal T cell differentiation |
J:81564
|
\H2b/\H2b
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal double-negative T cell morphology |
J:131357
|
|
abnormal double-positive T cell morphology |
J:81564
|
|
abnormal negative T cell selection |
J:81564
|
|
abnormal T cell differentiation |
J:81564
|
|
decreased double-positive T cell number |
J:131357
|
|
decreased thymocyte number |
J:131357
|
\H2b/\H2d
\Tg(TcraTcrb)1100Mjb/?
involves: BALB/c * C57BL/6
|
abnormal negative T cell selection |
J:133645
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133645
|
|
small thymus |
J:133645
|
\H2b/\H2g7
\Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * NOD * SJL
|
abnormal mitral valve morphology |
J:275827
|
|
increased hydroxyproline level |
J:275827
|
|
mitral valve inflammation |
J:275827
|
|
rheumatoid arthritis |
J:36815,
J:275827
|
|
thick mitral valve |
J:275827
|
\H2b/\H2k
\Itktm1Ljb/\Itktm1Ljb
\Tg(TcrAND)53Hed/?
involves: C3H/HeJ * C57BL/6 * C57BL/10
|
abnormal positive T cell selection |
J:123795
|
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
\H2b/\H2k
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * C57BL/10Sg * C57BR/c
|
abnormal negative T cell selection |
J:133645
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133645
|
|
small thymus |
J:133645
|
\H2b/\H2s
\Tg(TcraTcrb)1100Mjb/?
involves: A/WySn * C57BL/6 * C57BL/10Sg * Swiss
|
abnormal negative T cell selection |
J:133645
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133645
|
|
small thymus |
J:133645
|
\H2d/\H2d
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraN15,TcrbN15)L2Elre/?
involves: 129S/SvEv * C57BL/6
|
arrested T cell differentiation |
J:133112
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133112
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133112
|
\H2d/\H2d
\Tcra/Tcrdtm1.1(Tcra)Rsky/\Tcra/Tcrdtm1.1(Tcra)Rsky
\Tg(Tcrb)93Vbo/0
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
|
decreased thymocyte number |
J:131357
|
\H2d/\H2d
\Tg(TcraP1.5,TcrbP1.5)29Amsv/0
\Trap1atm1.1Jvde/Y
involves: 129 * BALB/cJ * C57BL/10 * DBA/2
|
abnormal T cell clonal deletion |
J:180807
|
\H2g7/\H2g7
\Ins2tm1Jja/\Ins2tm1Jja
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
increased circulating glucose level |
J:111874
|
|
increased susceptibility to autoimmune diabetes |
J:111874
|
\H2g7/\H2g7
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
increased susceptibility to autoimmune diabetes |
J:111874
|
|
insulitis |
J:111874
|
\H2g7/\H2g7
\Tg(Ins2-Vtcn1)#Xxz/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: C57BL/6 * NOD * SJL
|
decreased interferon-gamma secretion |
J:177612
|
|
decreased interleukin-17 secretion |
J:177612
|
|
decreased regulatory T cell number |
J:177612
|
|
decreased susceptibility to autoimmune diabetes |
J:177612
|
\H2g7/\H2g7
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0
B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
increased susceptibility to autoimmune diabetes |
J:167508
|
\H2g7/\H2g7
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
B6.Cg-H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased susceptibility to autoimmune diabetes |
J:86926
|
\H2g7/\H2g7
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
decreased susceptibility to autoimmune diabetes |
J:111874
|
|
insulitis |
J:111874
|
\H2g7/\H2q
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
increased susceptibility to autoimmune diabetes |
J:111874
|
\H2k/\H2k
\Tg(TcraTcrbAD10)1Hed/?
involves: C57BL/6 * SJL
|
increased CD4-positive, alpha-beta T cell number |
J:124701
|
\H2q/\H2q
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
decreased susceptibility to autoimmune diabetes |
J:111874
|
|
normal
digestive/alimentary phenotype |
J:111874
|
\H2u/\H2u
\Tg(TCRA)B1Jg/0
B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J
|
abnormal thymus cell ratio |
J:92992
|
|
decreased CD4-positive, alpha-beta T cell number |
J:92992
|
|
decreased double-positive T cell number |
J:92992
|
|
decreased thymocyte number |
J:92992
|
|
increased double-negative T cell number |
J:92992
|
|
increased T cell derived lymphoma incidence |
J:92992
|
\H2u/\H2u
\Tg(TCRA)B1Jg/0
\Tg(TCRB)C14Jg/0
B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg
|
abnormal double-negative T cell morphology |
J:92992
|
|
abnormal double-positive T cell morphology |
J:92992
|
|
abnormal thymus cell ratio |
J:92992
|
|
absent gamma-delta T cells |
J:92992
|
|
decreased double-positive T cell number |
J:92992
|
|
increased CD4-positive, alpha-beta T cell number |
J:92992
|
|
increased double-negative T cell number |
J:92992
|
|
increased T cell derived lymphoma incidence |
J:92992
|
\H2u/\H2u
\Tg(TCRA)B1Jg/?
\Tg(TCRB)C14Jg/?
involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:92991
|
|
abnormal effector T cell morphology |
J:92991
|
|
decreased CD8-positive, alpha-beta T cell number |
J:92991
|
|
decreased double-positive T cell number |
J:92991
|
|
increased autoantibody level |
J:92991
|
|
increased CD4-positive, alpha-beta T cell number |
J:92991
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:92991
|
|
paralysis |
J:92991
|
\Havcr2tm1Vlcg/\Havcr2tm1Vlcg
\Tg(TcraTcrb)1100Mjb/?
B6.Cg-Havcr2tm1Vlcg Tg(TcraTcrb)1100Mjb
|
decreased interferon-gamma secretion |
J:209885
|
|
decreased T cell number |
J:209885
|
\Hcls1tm1Wtn/\Hcls1tm1Wtn
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:28146
|
|
decreased double-positive T cell number |
J:28146
|
\Hivep2tm1Sis/\Hivep2tm1Sis
\Tg(DO11.10)10Dlo/?
involves: BALB/cA * C3H * C57BL/6NCrlj * CBA/JNCrlj
|
abnormal positive T cell selection |
J:96024
|
|
abnormal T-helper 2 cell morphology |
J:96024
|
|
decreased single-positive T cell number |
J:72249
|
\Icostm1Flv/\Icostm1Flv
\Tg(TcraTcrb)425Cbn/0
involves: 129S1/Sv * C57BL/6
|
abnormal cytokine secretion |
J:112600
|
\Id2tm1Ago/\Id2tm1Ago
\Tg(TcraTcrb)1100Mjb/0
B6.Cg-Id2tm1Ago Tg(TcraTcrb)1100Mjb
|
abnormal T cell activation |
J:116119
|
\Ido2em1Lamn/\Ido2em1Lamn
\Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * C57BL/6J * SJL
|
autoimmune arthritis |
J:342726
|
\Ido2em2Lamn/\Ido2em2Lamn
\Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * C57BL/6J * SJL
|
autoimmune arthritis |
J:342726
|
\Ifngtm1Ts/\Ifngtm1Ts
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
\Tg(Cd4-cre)1Cwi/0
involves: 129 * C57BL/6 * DBA/2 * NOD * SJL
|
normal
immune system phenotype |
J:196160
|
|
normal
mortality/aging |
J:196160
|
\Igh-Jtm1Aigl/\Igh-J+
\Mogtm1Dpd/\Mogtm1Dpd
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
|
abnormal nervous system morphology |
J:151335
|
|
abnormal optic nerve morphology |
J:151335
|
|
abnormal spinal cord morphology |
J:151335
|
|
CNS inflammation |
J:151335
|
|
demyelination |
J:151335
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
|
muscle hypertonia |
J:151335
|
|
paralysis |
J:151335
|
\Igh-Jtm1Aigl/\Igh-J+
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal nervous system morphology |
J:151335
|
|
abnormal optic nerve morphology |
J:151335
|
|
abnormal spinal cord morphology |
J:151335
|
|
CNS inflammation |
J:151335
|
|
demyelination |
J:151335
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
|
muscle hypertonia |
J:151335
|
|
paralysis |
J:151335
|
\Igh-Jtm1Aigl/\Igh-Jtm1Aigl
\Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J
|
increased autoantibody level |
J:149511
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:149511
|
\Igh-Jtm1Mcdl/\Igh-Jtm1Mcdl
\Igk-Jtm1Mcdl/\Igk-Jtm1Mcdl
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(DO11.10)10Dlo/?
involves: 129S/Sv * BALB/c * C3H * C57BL/6
|
abnormal spleen germinal center morphology |
J:100072
|
|
abnormal T cell differentiation |
J:100072
|
|
increased IgE level |
J:100072
|
|
increased IgG level |
J:100072
|
\Ighmtm1Cgn/\Ighmtm1Cgn
\Tg(TcraR28,TcrbR28)KRNDim/0
involves: 129S2/SvPas * C57BL/6 * NOD * SJL
|
normal
immune system phenotype |
J:36815
|
\Igktm1Dhu/\Igktm1Dhu
\Tg(H2-Ea-HA)HACIIAjca/0
\Tg(Tcra/Tcrb)1Vbo/0
C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo
|
autoimmune arthritis |
J:209872
|
\Il2tm1Hor/\Il2tm1Hor
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Tcra5CC7,Tcrb5CC7)IWep/0
involves: 129P2/OlaHsd * C57BL/10
|
abnormal T cell number |
J:120176
|
|
increased T-helper 17 cell number |
J:120176
|
\Il2tm1Hor/\Il2tm1Hor
\Tg(DO11.10)10Dlo/?
C.Cg-Il2tm1Hor Tg(DO11.10)10Dlo
|
abnormal regulatory T cell physiology |
J:88349
|
|
increased activated T cell number |
J:88349
|
|
increased T cell proliferation |
J:88349
|
|
premature death |
J:88349
|
\Il2tm1Hor/\Il2tm1Hor
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?
C.Cg-Il2tm1Hor Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo
|
abnormal regulatory T cell physiology |
J:112603
|
|
decreased regulatory T cell number |
J:112603
|
|
increased regulatory T cell number |
J:112603
|
\Il2ratm1Dw/\Il2ratm1Dw
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?
C.Cg-Il2ratm1Dw Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo
|
abnormal regulatory T cell physiology |
J:112603
|
|
decreased regulatory T cell number |
J:112603
|
|
increased regulatory T cell number |
J:112603
|
\Il4tm1Cgn/\Il4tm1Cgn
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
NOD.Cg-Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased susceptibility to autoimmune diabetes |
J:85924
|
|
insulitis |
J:85924
|
\Il6sttm1Thir/\Il6sttm1Thir
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129 * C57BL/6 * DBA
|
abnormal negative T cell selection |
J:133059
|
\Il13tm1.1Anjm/\Il13tm1.1Anjm
\Tg(DO11.10)10Dlo/0
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:91403
|
|
decreased interleukin-13 secretion |
J:91403
|
\Il15ratm1.1Nsl/\Il15ratm1.1Nsl
\Tg(TcrAND)53Hed/?
involves: 129X1/SvJ * C57BL/6 * SJL
|
increased T cell proliferation |
J:92705
|
\Itktm1Litt/\Itktm1Litt
\Tg(DO11.10)10Dlo/0
involves: 129S4/SvJae * BALB/c * C3H * C57BL/6J
|
abnormal T-helper 2 physiology |
J:129883
|
\Itktm1Litt/\Itktm1Litt
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S4/SvJae * C57BL/6 * DBA/2J
|
abnormal positive T cell selection |
J:31230
|
|
decreased CD4-positive, alpha-beta T cell number |
J:31230
|
|
increased double-positive T cell number |
J:31230
|
\Itktm1Litt/\Itktm1Litt
\Tg(TcrAND)53Hed/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal lymphocyte morphology |
J:31230
|
|
decreased CD4-positive, alpha-beta T cell number |
J:31230
|
|
increased double-negative T cell number |
J:31230
|
\Itktm1Ljb/\Itktm1Ljb
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Tcra5CC7,Tcrb5CC7)IWep/?
involves: 129 * C57BL/10
|
abnormal CD4-positive T cell differentiation |
J:93606
|
|
decreased interferon-gamma secretion |
J:93606
|
|
decreased interleukin-4 secretion |
J:93606
|
|
decreased interleukin-5 secretion |
J:93606
|
|
decreased interleukin-10 secretion |
J:93606
|
\Itktm1Ljb/\Itktm1Ljb
\Tg(Tcra2B4)1Mmd/?
\Tg(Tcrb2B4)1Mmd/?
involves: C3H/HeJ * C57BL/6 * C57BL/10
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
\Itktm1Ljb/\Itktm1Ljb
\Tg(Tcra5CC7,Tcrb5CC7)IWep/?
involves: 129 * C57BL/10
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
\Itktm1Ljb/\Itktm1Ljb
\Tg(TcraTcrb)1100Mjb/?
involves: 129 * C57BL/6 * C57BL/10
|
normal
immune system phenotype |
J:113408
|
\Ksr1tm1Shaw/\Ksr1tm1Shaw
\Tg(DO11.10)10Dlo/0
involves: BALB/c * C3H * C57BL/6
|
abnormal CD4-positive T cell differentiation |
J:75739
|
|
decreased interleukin-2 secretion |
J:75739
|
|
decreased T cell proliferation |
J:75739
|
\Lattm6.1(HBEGF/EGFP)Mal/?
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
abnormal T cell physiology |
J:138401
|
\Lcktm1Dbs/\Lcktm1Dbs
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C3H * C57BL/6 * DBA/2J
|
abnormal positive T cell selection |
J:114660
|
|
abnormal T cell differentiation |
J:114660
|
|
arrested T cell differentiation |
J:114660
|
\Lcktm1Dbs/\Lcktm1Dbs
\Tg(TcraTcrb)425Cbn/0
involves: C3H * C57BL/6
|
abnormal positive T cell selection |
J:114660
|
|
arrested T cell differentiation |
J:114660
|
\Lcktm1Dbs/\Lcktm1Dbs
\Tg(TcraTcrb)1100Mjb/0
involves: C3H * C57BL/6
|
abnormal positive T cell selection |
J:114660
|
|
decreased T cell proliferation |
J:114660
|
\Lcp2tm1.1Wz/\Lcp2tm1.1Wz
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:150304
|
\Lcp2tm3Gak/\Lcp2tm3Gak
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S6/SvEvTac * C57BL/6 * DBA/2J
|
abnormal negative T cell selection |
J:132995
|
|
normal
immune system phenotype |
J:132995
|
|
increased CD8-positive, alpha-beta T cell number |
J:132995
|
|
increased double-positive T cell number |
J:132995
|
\Lcp2tm3Gak/\Lcp2tm3Gak
\Tg(TcrAND)53Hed/?
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:132995
|
|
abnormal thymocyte activation |
J:132995
|
\Lcp2tm4Gak/\Lcp2tm4Gak
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S6/SvEvTac * C57BL/6 * DBA * FVB/N
|
abnormal negative T cell selection |
J:132995
|
|
increased double-positive T cell number |
J:132995
|
\Lcp2tm4Gak/\Lcp2tm4Gak
\Tg(TcrAND)53Hed/?
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:132995
|
|
abnormal thymocyte activation |
J:132995
|
\Lime1tm1.1Mal/\Lime1tm1.1Mal
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?
B6.Cg-Rag2tm1Fwa Lime1tm1.1Mal Tg(TcraH-Y,TcrbH-Y)1Pas
|
abnormal CD4-positive T cell differentiation |
J:126321
|
|
increased CD4-positive, alpha-beta T cell number |
J:126321
|
\Map2k6tm1Ina/\Map2k6tm1Ina
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal thymus cell ratio |
J:100093
|
|
decreased apoptosis |
J:100093
|
\Map2k6tm1Ina/\Map2k6tm1Ina
\Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
decreased apoptosis |
J:100093
|
\Mapk1tm1Hed/\Mapk1tm1Hed
\Mapk3tm1Gpg/\Mapk3tm1Gpg
\Tg(Cd4-cre)1Cwi/0
\Tg(TcrAND)53Hed/0
involves: 129/Sv * C57BL/6 * DBA/2 * SJL
|
abnormal positive T cell selection |
J:113280
|
|
abnormal T cell subpopulation ratio |
J:113280
|
\Mapk1tm1Hed/\Mapk1tm1Hed
\Mapk3tm1Gpg/\Mapk3tm1Gpg
\Tg(TcraTcrb)1100Mjb/0
involves: 129/Sv * C57BL/6
|
decreased thymocyte number |
J:113280
|
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(Lck-cre)1Cwi/0
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * DBA/2 * SJL
|
abnormal positive T cell selection |
J:113280
|
|
abnormal T cell subpopulation ratio |
J:113280
|
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * DBA/2 * SJL
|
abnormal double-positive T cell morphology |
J:113280
|
|
abnormal positive T cell selection |
J:113280
|
\Mapk1tm1Hed/\Mapk1tm1Hed
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
decreased thymocyte number |
J:113280
|
\Mcl1tm1Yen/\Mcl1tm1Yen
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
abnormal double-positive T cell morphology |
J:146246
|
|
decreased CD8-positive, alpha-beta T cell number |
J:146246
|
\Mcl1tm1Yen/\Mcl1tm1Yen
\Tg(TcraTcrb)425Cbn/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal double-positive T cell morphology |
J:146246
|
|
decreased CD4-positive, alpha-beta T cell number |
J:146246
|
\Mertktm1Gkm/\Mertktm1Gkm
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
NOD.Cg-Mertktm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased double-positive T cell number |
J:147153
|
|
increased CD8-positive, alpha-beta T cell number |
J:147153
|
|
increased T cell apoptosis |
J:147153
|
\Mirc14tm1.2Flv/\Mirc14tm1.2Flv
\Tg(Cd4-TcraDN32D3)1Aben/0
involves: C57BL/6 * C57BL/6N * FVB/N * SJL
|
abnormal NK T cell physiology |
J:203157
|
|
decreased NK T cell number |
J:203157
|
\Mogtm1(cre)Gkl/\Mogtm1(cre)Gkl
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
C57BL/6-Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
\Mogtm1Dpd/\Mogtm1Dpd
\Rag2tm1Cgn/\Rag2tm1Cgn
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas * C57BL/6
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
\Mogtm1Dpd/\Mogtm1Dpd
\Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
SJL.Cg-Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:149511
|
\Mogtm1Dpd/\Mogtm1Dpd
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas * C57BL/6
|
abnormal nervous system morphology |
J:151335
|
|
abnormal optic nerve morphology |
J:151335
|
|
abnormal spinal cord morphology |
J:151335
|
|
CNS inflammation |
J:151335
|
|
demyelination |
J:151335
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
|
muscle hypertonia |
J:151335
|
|
paralysis |
J:151335
|
\Mpztm1Msch/\Mpz+
\Tcratm1Mjo/\Tcratm1Mjo
involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6
|
abnormal myelin sheath morphology |
J:59319
|
|
abnormal nerve conduction |
J:59319
|
|
abnormal nervous system physiology |
J:59319
|
|
abnormal neuron morphology |
J:59319
|
|
decreased nerve conduction velocity |
J:59319
|
|
decreased T cell number |
J:59319
|
|
increased Schwann cell number |
J:59319
|
\Myo1gtm1.2Mfk/\Myo1gtm1.2Mfk
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * FVB/N * SJL
|
abnormal T cell physiology |
J:212451
|
\Ncaph2nes/\Ncaph2nes
\Tg(TcrHEL3A9)1Mmd/0
C57BL/6-Ncaph2nes Tg(TcrHEL3A9)1Mmd
|
abnormal double-negative T cell morphology |
J:123300
|
|
abnormal thymus cell ratio |
J:123300
|
|
decreased double-positive T cell number |
J:123300
|
\Ndfip1Gt(RRD002)Byg/\Ndfip1Gt(RRD002)Byg
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6
|
normal
immune system phenotype |
J:205692
|
\Nfatc3tm1Glm/\Nfatc3tm1Glm
\Tg(DO11.10)10Dlo/?
involves: 129S2/SvPas * BALB/c * C3H * C57BL/6
|
decreased double-positive T cell number |
J:50124
|
|
increased double-negative T cell number |
J:50124
|
|
small thymus |
J:50124
|
\Notch1tm1Agt/\Notch1tm1Agt
\Notch2tm3Grid/\Notch2tm3Grid
\Tg(TcrAND)53Hed/?
involves: 129/Sv * 129S1/Sv * C57BL/6 * SJL
|
abnormal humoral immune response |
J:123631
|
|
abnormal response to infection |
J:123631
|
|
decreased interleukin-4 secretion |
J:123631
|
\Nr3c1tm1.1Jda/\Nr3c1tm1.1Jda
\Rag2tm1.1Cgn/\Rag2tm1.1Cgn
\Tg(Lck-cre)548Jxm/0
\Tg(TcrAND)53Hed/0
B6.Cg-Rag2tm1.1Cgn Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm Tg(TcrAND)53Hed
|
decreased double-positive T cell number |
J:189951
|
\Nr3c1tm1.1Jda/\Nr3c1tm1.1Jda
\Tcratm1Mom/\Tcratm1Mom
\Tg(Lck-cre)548Jxm/0
B6.Cg-Tcratm1Mom Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm
|
decreased double-positive T cell number |
J:189951
|
\Patz1tm1.1Welm/\Patz1tm1.1Welm
\Tg(TcraTcrb)425Cbn/0
involves: C57BL/6
|
abnormal T cell subpopulation ratio |
J:158947
|
|
decreased CD8-positive, alpha-beta T cell number |
J:158947
|
|
increased CD4-positive, alpha-beta T cell number |
J:158947
|
\Patz1tm1.1Welm/\Patz1tm1.1Welm
\Tg(TcraTcrb)1100Mjb/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell subpopulation ratio |
J:158947
|
|
decreased CD8-positive, alpha-beta T cell number |
J:158947
|
|
increased CD4-positive, alpha-beta T cell number |
J:158947
|
\Pdcd1tm1.1Shr/\Pdcd1tm1.1Shr
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
abnormal immune tolerance |
J:153040
|
|
decreased T cell proliferation |
J:153040
|
|
increased susceptibility to autoimmune diabetes |
J:153040
|
|
increased T cell proliferation |
J:153040
|
|
insulitis |
J:153040
|
|
pancreas inflammation |
J:153040
|
|
vascular inflammation |
J:153040
|
\Pdcd1tm1Hon/\Pdcd1tm1Hon
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:140751
|
\Pdcd1tm1Hon/\Pdcd1tm1Hon
\Vsirtm1Lex/\Vsirtm1Lex
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:222944
|
\Pgdtm1.1Pse/\Pgdtm1.1Pse
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraTcrb)8Rest/0
involves: C57BL/6 * DBA/2
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:306553
|
\Pgdtm1.1Pse/\Pgdtm1.1Pse
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * DBA/2
|
abnormal cytotoxic T cell physiology |
J:306553
|
\Pik3cgtm1Dwu/\Pik3cgtm1Dwu
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:131923
|
|
abnormal response to infection |
J:131923
|
|
normal
immune system phenotype |
J:131923
|
\Pip5k1ctm1.2Ref/\Pip5k1ctm1.2Ref
\Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
abnormal T cell physiology |
J:164732
|
|
decreased B cell number |
J:164732
|
|
decreased dendritic cell number |
J:164732
|
|
increased interferon-gamma secretion |
J:164732
|
|
increased interleukin-2 secretion |
J:164732
|
|
increased T cell proliferation |
J:164732
|
\Plcg1tm1Gcrp/\Plcg1tm1Rwen
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129X1/SvJ * C57BL/6 * DBA/2
|
decreased CD8-positive, alpha-beta T cell number |
J:157757
|
|
decreased double-negative T cell number |
J:157757
|
|
increased CD8-positive, alpha-beta T cell number |
J:157757
|
|
increased double-positive T cell number |
J:157757
|
|
thymus hyperplasia |
J:157757
|
\Plxna1tm1Kik/\Plxna1tm1Kik
\Tg(TcraTcrb)425Cbn/?
involves: BALB/c * C57BL/6
|
decreased T cell proliferation |
J:161856
|
\Ppp4ctm1Tht/\Ppp4ctm1Tht
\Tg(Lck-cre)548Jxm/0
\Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6 * CBA
|
abnormal positive T cell selection |
J:117684
|
|
decreased double-positive T cell number |
J:117684
|
|
decreased single-positive T cell number |
J:117684
|
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tcratm1Mom/\Tcratm1Mom
involves: 129P2/OlaHsd * 129S2/SvPas
|
decreased interleukin-4 secretion |
J:135589
|
|
decreased T cell proliferation |
J:135589
|
|
normal
digestive/alimentary phenotype |
J:135589
|
|
normal
immune system phenotype |
J:135589
|
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tg(DO11.10)10Dlo/0
involves: 129 * BALB/c * C3H * C57BL/6
|
decreased T cell apoptosis |
J:141930
|
\Prkcqtm1Litt/\Prkcqtm1Litt
\Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal T cell anergy |
J:123989
|
|
decreased cytotoxic T cell cytolysis |
J:123989
|
|
decreased splenocyte proliferation |
J:123989
|
|
decreased T cell proliferation |
J:123989
|
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(Lck-cre)1Jtak/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6 * C57BL/6J * DBA/2J
|
decreased thymocyte number |
J:236298
|
|
increased double-positive T cell number |
J:236298
|
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(Lck-cre)1Jtak/0
\Tg(TcraTcrb)425Cbn/0
involves: 129 * BALB/c * C57BL/6
|
decreased thymocyte number |
J:236298
|
\Prkd2tm1.1Shoy/\Prkd2tm1.1Shoy
\Prkd3tm1.1Shoy/\Prkd3tm1.1Shoy
\Tg(Lck-cre)1Jtak/0
\Tg(TcraTcrb)1100Mjb/0
involves: 129 * C57BL/6
|
decreased thymocyte number |
J:236298
|
\Prkdcscid/\Prkdcscid
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0
NOD.Cg-Prkdcscid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
abnormal CD4-positive, alpha beta T cell morphology |
J:93553
|
|
increased susceptibility to autoimmune diabetes |
J:93553
|
\Prkdcscid/\Prkdcscid
\Tg(TcrLCMV)327Sdz/?
NOD.Cg-Emv30b Prkdcscid Tg(TcrLCMV)327Sdz/DvsJ
|
normal
immune system phenotype |
J:71050
|
\Prss16tm1.1Mal/\Prss16+
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
abnormal positive T cell selection |
J:148034
|
|
decreased CD4-positive, alpha-beta T cell number |
J:148034
|
|
decreased single-positive T cell number |
J:148034
|
|
lymph node hypoplasia |
J:148034
|
\Prss16tm1.1Mal/\Prss16tm1.1Mal
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)1Pas/?
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
abnormal positive T cell selection |
J:148034
|
|
decreased CD4-positive, alpha-beta T cell number |
J:148034
|
|
decreased double-positive T cell number |
J:148034
|
|
decreased single-positive T cell number |
J:148034
|
|
lymph node hypoplasia |
J:148034
|
|
spleen hypoplasia |
J:148034
|
|
thymus hypoplasia |
J:148034
|
\Psmb8tm1Hjf/\Psmb8tm1Hjf
\Tg(TcraTcrb)1100Mjb/?
involves: 129P2/OlaHsd * C57BL/6
|
decreased CD8-positive, alpha-beta T cell number |
J:107657
|
\Ptpn22tm1.1Kas/\Ptpn22tm1.1Kas
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
normal
immune system phenotype |
J:176519
|
\Ptpn22tm1.1Kas/\Ptpn22tm1.1Kas
\Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
increased CD4-positive, alpha-beta T cell number |
J:176519
|
|
increased T cell proliferation |
J:176519
|
\Ptprcltng/\Ptprctm1Mak
\Tg(TcraTcrb)425Cbn/0
involves: 129/Sv * BALB/c * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:158876
|
|
thymus hypoplasia |
J:158876
|
\Ptprctm1Mak/\Ptprctm1Mak
\Tg(TcraTcrb)425Cbn/0
involves: 129/Sv * BALB/c * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:158876
|
\Rac2tm1Mddw/\Rac2tm1Mddw
\Tg(TcrAND)53Hed/0
involves: 129S/SvEv * C57BL/6 * SJL
|
abnormal T cell activation |
J:119437
|
|
decreased circulating interleukin-2 level |
J:119437
|
|
decreased T cell proliferation |
J:119437
|
\Rag1tm1Bal/\Rag1tm1Bal
\Tg(TcraTcrb)1100Mjb/?
involves: 129S4/SvJae * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:133645
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133645
|
|
increased CD8-positive, alpha-beta T cell number |
J:133645
|
\Rag1tm1Bal/\Rag1tm1Bal
\Vav1tm2Tyb/\Vav1tm2Tyb
\Tg(TcrAND)53Hed/0
involves: 129S4/SvJae * 129S8/SvEv * C57BL/6 * SJL
|
decreased CD4-positive, alpha-beta T cell number |
J:113270
|
\Rag1tm1Mom/\Rag1+
\Tg(LPV-TAg1135)11Tvd/0
\Tg(TcrLCMV)327Sdz/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2
|
increased T cell derived lymphoma incidence |
J:47667
|
|
premature death |
J:47667
|
\Rag1tm1Mom/\Rag1tm1Mom
\Slc46a2tm1Moki/\Slc46a2+
\Tg(TcraB12,TcrbB12)1Rest/0
involves: 129 * C57BL/6
|
arrested T cell differentiation |
J:140121
|
|
decreased double-positive T cell number |
J:140121
|
|
increased T cell apoptosis |
J:140121
|
|
thymus hypoplasia |
J:140121
|
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(LPV-TAg1135)11Tvd/0
\Tg(TcrLCMV)327Sdz/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2
|
increased T cell derived lymphoma incidence |
J:47667
|
|
premature death |
J:47667
|
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(Tcra,Tcrb)HRCAll/0
B6.Cg-Rag1tm1Mom Tg(Tcra,Tcrb)HRCAll
|
abnormal T cell differentiation |
J:131347
|
|
abnormal T cell subpopulation ratio |
J:131347
|
|
absent CD4-positive, alpha-beta T cells |
J:131347
|
|
increased CD8-positive, alpha-beta T cell number |
J:131347
|
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0
NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs
|
increased susceptibility to autoimmune diabetes |
J:94192
|
\Rag1tm1Mom/\Rag1tm1Mom
\Tg(TcraBDC12-4.1)10Jos/0
\Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
decreased CD4-positive, alpha-beta T cell number |
J:111874
|
|
decreased lymphocyte cell number |
J:111874
|
|
decreased pancreatic beta cell number |
J:111874
|
|
decreased thymus weight |
J:111874
|
|
increased circulating glucose level |
J:111874
|
|
increased double-positive T cell number |
J:111874
|
|
increased susceptibility to autoimmune diabetes |
J:111874
|
\Rag1tm1Mom/\Rag1tm1Mom
\Tyrp1B-w/\Tyrp1B-w
X/\Tg(Tcra,Tcrb)9Rest
involves: 101/Rl * 129S7/SvEvBrd * C3H/Rl * C57BL/6
|
abnormal tumor susceptibility |
J:138466
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\TcraLn3Jae/\Tcra+
\TcrbLn3Jae/\Tcrb+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6
|
abnormal double-negative T cell morphology |
J:143006
|
|
absent gamma-delta T cells |
J:143006
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143006
|
|
increased CD8-positive, alpha-beta T cell number |
J:143006
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Cd4-NPM/ALK)N1Ingh/0
\Tg(TcraTcrb)1100Mjb/0
involves: 129S/SvEv * C57BL/6 * Swiss Webster
|
increased gastrointestinal stromal tumor incidence |
J:235890
|
|
increased hepatocellular carcinoma incidence |
J:235890
|
|
increased sarcoma incidence |
J:235890
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(DO11.10)10Dlo/0
involves: 129S/SvEv * BALB/c * C3H * C57BL/6
|
normal
immune system phenotype |
J:110446
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Tcra5CC7,Tcrb5CC7)IWep/?
\Themis5AT161/\Themis5AT161
involves: 129S/SvEv * C57BL/6
|
arrested T cell differentiation |
J:151076
|
|
increased double-positive T cell number |
J:151076
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0
involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA/2
|
abnormal CD4-positive T cell differentiation |
J:125548
|
|
abnormal positive T cell selection |
J:125548
|
|
decreased CD4-positive, alpha-beta T cell number |
J:125548
|
|
increased double-positive T cell number |
J:125548
|
|
thymus hyperplasia |
J:125548
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraCN.B1,TcrbCN.B1)SM1Jen/0
involves: 129S/SvEv * C57BL/6
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:162539
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S/SvEv * C57BL/6J * DBA/2J
|
abnormal CD8-positive, alpha beta T cell morphology |
J:125259
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:125259
|
|
abnormal cytotoxic T cell physiology |
J:66565
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
\Themis5AT161/\Themis5AT161
involves: 129S/SvEv * C57BL/6 * DBA/2
|
decreased single-positive T cell number |
J:151076
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcraTcrbNY8.3)1Pesa/0
NOD.Cg-Rag2tm1Fwa Tg(TcraTcrbNY8.3)1Pesa
|
increased circulating glucose level |
J:94192
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcrHEL3A9)1Mmd/0
involves: 129S/SvEv * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal double-positive T cell morphology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
abnormal thymus cell ratio |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
\Rag2tm1Fwa/\Rag2tm1Fwa
\Tg(TcrHEL3A9)1Mmd/0
\Tg(TLK2mHEL)2Ccg/0
involves: 129S/SvEv * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
|
thyroid gland inflammation |
J:78309
|
\Rasgrp1tm1.1Wz/\Rasgrp1tm1.1Wz
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6J * DBA/2J
|
decreased single-positive T cell number |
J:225109
|
|
increased double-positive T cell number |
J:225109
|
\Rasgrp1tm1.1Wz/\Rasgrp1tm1.1Wz
\Tg(TcraTcrb)425Cbn/?
involves: C57BL/6 * BALB/c
|
abnormal CD4-positive T cell differentiation |
J:225109
|
\Rhohtm1Brak/\Rhohtm1Brak
\Tg(TcraTcrb)425Cbn/?
involves: 129/Sv * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:143161
|
|
normal
immune system phenotype |
J:143161
|
\Rinltm1.1Boun/\Rinltm1.1Boun
\Tg(TcraTcrb)425Cbn/0
involves: C57BL/6
|
abnormal T follicular helper cell differentiation |
J:346452
|
|
increased CD4-positive, alpha-beta T cell number |
J:346452
|
|
increased T follicular helper cell number |
J:346452
|
\Rnf128tm1.1Flv/\Rnf128tm1.1Flv
\Tg(TcraTcrb)425Cbn/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6
|
abnormal peripheral T cell anergy |
J:153216
|
|
decreased T cell proliferation |
J:153216
|
|
increased circulating interleukin-2 level |
J:153216
|
\Rnf128tm1.1Flv/Y
\Tg(TcraTcrb)425Cbn/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6
|
abnormal peripheral T cell anergy |
J:153216
|
|
decreased T cell proliferation |
J:153216
|
|
increased circulating interleukin-2 level |
J:153216
|
\Rnf128tm1Cdon/\Rnf128tm1Cdon
\Tg(TcraTcrb)425Cbn/0
involves: 129 * BALB/c * C57BL/6
|
abnormal immune tolerance |
J:160681
|
|
increased interferon-gamma secretion |
J:160681
|
|
increased interleukin-2 secretion |
J:160681
|
|
increased splenocyte proliferation |
J:160681
|
\Rr79em2Rtew/\Rr79em2Rtew
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6J
|
abnormal T cell activation |
J:332957
|
\Rr100tm2.1Welm/\Rr100tm2.1Welm
\Tcratm1Mom/\Tcratm1Mom
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal T cell morphology |
J:113136
|
\Rr381em2Kap/\Rr381em2Kap
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
hematopoietic system phenotype |
J:333471
|
\Rr381em2Kap/\Rr381em2Kap
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
normal
hematopoietic system phenotype |
J:333471
|
\Serpina3gtm1.1Arp/\Serpina3gtm1.1Arp
\Tg(TcrLCMV)#Sdz/0
involves: C57BL/6 * DBA/2
|
decreased T cell proliferation |
J:189782
|
\Serpinb9tm1Arp/\Serpinb9tm1Arp
\Tg(TcrLCMV)327Sdz/0
involves: C57BL/6
|
abnormal response to transplant |
J:113349
|
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Slamf6tm1Pls/\Slamf6tm1Pls
\Tg(TcraTcrb)1100Mjb/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J
|
normal
immune system phenotype |
J:187431
|
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Tg(DO11.10)10Dlo/\Tg(DO11.10)10Dlo
involves: BALB/c * C3H * C57BL/6
|
abnormal cytokine secretion |
J:90484
|
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:157915
|
\Sh2d1atm1Pls/\Sh2d1atm1Pls
\Tg(TcraTcrb)1100Mjb/0
involves: 129S6/SvEvTac * C57BL/6
|
abnormal cytotoxic T cell physiology |
J:187431
|
|
decreased cytotoxic T cell cytolysis |
J:187431
|
|
decreased interferon-gamma secretion |
J:187431
|
\Sit1tm1Lsmn/\Sit1tm1Lsmn
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal CD8-positive, alpha beta T cell morphology |
J:100408
|
|
abnormal positive T cell selection |
J:100408
|
|
abnormal T cell differentiation |
J:100408
|
\Sit1tm1Lsmn/\Sit1tm1Lsmn
\Tg(TcrLCMV)327Sdz/0
involves: C57BL/6
|
abnormal positive T cell selection |
J:100408
|
|
abnormal T cell selection |
J:100408
|
|
thymus hypoplasia |
J:100408
|
\Slatm1Weis/\Slatm1Weis
\Tg(DO11.10)10Dlo/0
involves: 129 * BALB/c * C3H * C57BL/6
|
abnormal positive T cell selection |
J:71804
|
|
abnormal T cell differentiation |
J:71804
|
\Slamf1tm1Cpt/\Slamf1tm1Cpt
\Tg(DO11.10)10Dlo/\Tg(DO11.10)10Dlo
involves: BALB/c * C3H * C57BL/6
|
abnormal cytokine secretion |
J:90484
|
\Slamf6tm1Pls/\Slamf6tm1Pls
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * C57BL/6J
|
normal
immune system phenotype |
J:187431
|
\Stat2tm1Jdf/\Stat2tm1Jdf
\Tg(DO11.10)10Dlo/0
C.Cg-Stat2tm1Jdf Tg(DO11.10)10Dlo
|
normal
immune system phenotype |
J:95855
|
\Tagln2tm1Cdj/\Tagln2tm1Cdj
\Tg(TcraTcrb)425Cbn/0
involves: 129S4/SvJae * C57BL/6
|
abnormal T cell activation |
J:256656
|
\Tagln2tm1Cdj/\Tagln2tm1Cdj
\Tg(TcraTcrb)1100Mjb/0
involves: 129S4/SvJae * C57BL/6
|
abnormal T cell activation |
J:256656
|
\Tapbptm1Luc/\Tapbptm1Luc
\Tg(TcraTcrb)1100Mjb/?
involves: 129S6/SvEvTac
|
normal
immune system phenotype |
J:64177
|
\Tapbptm1Luc/\Tapbptm1Luc
\Tg(TcraTcrb)1100Mjb/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:64177
|
|
abnormal CD8-positive, alpha beta T cell morphology |
J:64177
|
|
abnormal negative T cell selection |
J:64177
|
|
abnormal positive T cell selection |
J:64177
|
|
normal
immune system phenotype |
J:64177
|
\Tcf3tm4Zhu/\Tcf3tm4Zhu
\Tg(Lck-cre)#Zhu/0
\Tg(TcrAND)53Hed/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
normal
immune system phenotype |
J:75746
|
|
normal
neoplasm |
J:75746
|
\Tcf12tm2Zhu/\Tcf12tm2Zhu
\Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
abnormal CD4-positive, alpha beta T cell morphology |
J:120411
|
|
abnormal T cell subpopulation ratio |
J:120411
|
|
arrested T cell differentiation |
J:120411
|
|
increased T cell number |
J:120411
|
\TcraLn1Ogu/\Tcra+
\TcrbLn1Ogu/\Tcrb+
involves: 129/Sv * C57BL/6
|
abnormal T cell morphology |
J:152069
|
|
increased body weight |
J:152069
|
\TcraLn2Ogu/\Tcra+
\TcrbLn2Ogu/\Tcrb+
involves: 129/Sv * C57BL/6
|
abnormal T cell morphology |
J:152069
|
|
increased body weight |
J:152069
|
\TcraLn3Jae/\Tcra+
\TcrbLn3Jae/\Tcrb+
B6.Cg-TcrbLn3Jae TcraLn3Jae
|
abnormal double-negative T cell morphology |
J:143006
|
|
abnormal T cell differentiation |
J:143006
|
|
absent gamma-delta T cells |
J:143006
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143006
|
|
decreased double-positive T cell number |
J:143006
|
|
increased CD8-positive, alpha-beta T cell number |
J:143006
|
|
thymus hypoplasia |
J:143006
|
\Tcratm1Mjo/\Tcratm1Mjo
X/\Yaa
BXSB.129P2(Cg)-Tcratm1Mjo/Theo
|
normal
immune system phenotype |
J:120153
|
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\H2b/\H2b
\Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal double-negative T cell morphology |
J:131357
|
|
abnormal double-positive T cell morphology |
J:81564
|
|
abnormal negative T cell selection |
J:81564
|
|
abnormal T cell differentiation |
J:81564
|
|
decreased double-positive T cell number |
J:131357
|
|
decreased thymocyte number |
J:131357
|
\Tcratm1Mom/\Tcra/Tcrdtm1.1(Tcra)Rsky
\H2d/\H2d
\Ptcratm1Vbo/\Ptcratm1Vbo
\Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
|
decreased thymocyte number |
J:131357
|
\Tcratm1Mom/\Tcratm1Mom
\Tcra-Jtm1Kgwa/\Tcra-Jtm1Kgwa
involves: 129P2/OlaHsd * 129S2/SvPas * C3H/HeJ * C57BL/6J
|
increased double-negative T cell number |
J:50143
|
\Tcratm1Mom/\Tcratm1Mom
\Tcrbtm1Mom/\Tcrbtm1Mom
involves: 129 * BALB/c * C57BL/6
|
arrested T cell differentiation |
J:3206
|
|
decreased double-positive T cell number |
J:3206
|
|
thymus hypoplasia |
J:3206
|
\Tcratm1Mom/\Tcratm1Mom
\Tcrgtm1.1Hish/\Tcrgtm1.1Hish
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal large intestine morphology |
J:135597
|
|
absent gamma-delta T cells |
J:135597
|
|
colitis |
J:135597
|
|
impaired macrophage chemotaxis |
J:135597
|
|
impaired neutrophil recruitment |
J:135597
|
\Tcratm1Mom/\Tcratm1Mom
\Tg(CD19-Tnfsf7)#Rvl/0
involves: 129P2/OlaHsd * C57BL/6
|
absent T cells |
J:88620
|
\Tcratm1Mom/\Tcratm1Mom
\Tg(Lck-Akt1*E40K)E-3Pnt/0
involves: 129S2/SvPas * C3H/He * C57BL/6
|
arrested T cell differentiation |
J:135903
|
\Tcratm1Mom/\Tcratm1Mom
\Trex1tm1Tld/\Trex1tm1Tld
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
colitis |
J:181257
|
|
normal
immune system phenotype |
J:181257
|
|
increased inflammatory response |
J:181257
|
|
normal
mortality/aging |
J:181257
|
|
myositis |
J:181257
|
|
skin inflammation |
J:181257
|
\Tespa1tm1Smoc/\Tespa1tm1Smoc
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6 * DBA/2J
|
decreased CD8-positive, alpha-beta T cell number |
J:186446
|
\Tespa1tm1Smoc/\Tespa1tm1Smoc
\Tg(TcraTcrb)425Cbn/0
B6.Cg-Tespa1tm1Smoc Tg(TcraTcrb)425Cbn
|
abnormal T cell differentiation |
J:186446
|
|
decreased CD4-positive, alpha-beta T cell number |
J:186446
|
|
decreased CD8-positive, alpha-beta T cell number |
J:186446
|
\Tespa1tm1Smoc/\Tespa1tm1Smoc
\Tg(TcraTcrb)1100Mjb/0
B6.Cg-Tespa1tm1Smoc Tg(TcraTcrb)1100Mjb
|
abnormal T cell differentiation |
J:186446
|
|
decreased CD4-positive, alpha-beta T cell number |
J:186446
|
|
decreased CD8-positive, alpha-beta T cell number |
J:186446
|
\Tg(Alb1-GP33/H2-Kb)1Hpi/0
\Tg(Alb1-HBV)66Bri/0
\Tg(TcrLCMV)318Sdz/0
involves: C57BL/6 * C57BL/10 * DBA/2
|
liver inflammation |
J:162605
|
\Tg(Alb1-GP33/H2-Kb)1Hpi/0
\Tg(TcrLCMV)318Sdz/0
involves: C57BL/6 * DBA/2
|
decreased CD8-positive, alpha-beta T cell number |
J:162605
|
\Tg(CD2-Ceacam1*4L)1Rsb/0
\Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:116136
|
\Tg(CD2-Mir181d)38Oers/0
\Tg(TcraTcrb)425Cbn/0
involves: C3H * C57BL/6
|
decreased T cell number |
J:212571
|
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N
|
abnormal positive T cell selection |
J:126026
|
|
decreased CD4-positive, alpha-beta T cell number |
J:126026
|
|
increased CD8-positive, alpha-beta T cell number |
J:126026
|
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
involves: BALB/c * C57BL/10
|
decreased CD8-positive, alpha-beta T cell number |
J:113713
|
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
involves: C57BL/10
|
abnormal positive T cell selection |
J:113713
|
|
increased CD8-positive, alpha-beta T cell number |
J:113713
|
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
involves: C57BL/10 * CBA/Ca
|
decreased CD8-positive, alpha-beta T cell number |
J:113713
|
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
involves: C57BL/6 * C57BL/10
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
|
enlarged lymph nodes |
J:217939
|
|
increased T cell number |
J:217939
|
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
\Tg(LCKprBCL2)36Sjk/0
involves: C57BL/6 * C57BL/10
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
\Tg(CD2-Zbtb7b)C8Rbo/?
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * DBA/2J
|
abnormal T cell differentiation |
J:97610
|
\Tg(CD2-Zbtb7b)C8Rbo/?
\Tg(TcrLCMV)327Sdz/?
involves: C57BL/6 * DBA/2J
|
abnormal T cell differentiation |
J:97610
|
\Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
\Tg(Cd4-cre)1Cwi/?
\Tg(TcraTcrb)425Cbn/?
\Traf6tm2Ywc/\Traf6tm2Ywc
involves: C57BL/6 * DBA/2
|
abnormal lymphocyte anergy |
J:130882
|
|
increased interleukin-2 secretion |
J:130882
|
\Tg(Cd4-NPM/ALK)N1Ingh/0
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * Swiss Webster
|
abnormal double-negative T cell morphology |
J:235890
|
|
abnormal thymus morphology |
J:235890
|
|
increased gastrointestinal stromal tumor incidence |
J:235890
|
|
increased hepatocellular carcinoma incidence |
J:235890
|
|
increased sarcoma incidence |
J:235890
|
|
increased T cell derived lymphoma incidence |
J:235890
|
|
premature death |
J:235890
|
\Tg(Cd8aCd8b)3Erob/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * DBA/2
|
abnormal CD4-positive, alpha beta T cell morphology |
J:93004
|
|
abnormal CD8-positive, alpha-beta T cell differentiation |
J:93004
|
|
increased CD8-positive, alpha-beta T cell number |
J:93004
|
\Tg(CMV-TcrAHIII12.2)1Ecol/0
C57BL/6-Tg(CMV-TcrAHIII12.2)1Ecol
|
no abnormal phenotype detected |
J:94077
|
\Tg(CMV-TcrAHIII12.2)1Ecol/\Tg(CMV-TcrAHIII12.2)1Ecol
C57BL/6-Tg(CMV-TcrAHIII12.2)1Ecol
|
no abnormal phenotype detected |
J:94077
|
\Tg(DO11.10)10Dlo/?
involves: BALB/c * C3H * C57BL/6
|
abnormal thymus physiology |
J:70572
|
|
decreased CD4-positive, alpha-beta T cell number |
J:70572
|
|
decreased double-positive T cell number |
J:70572
|
\Tg(DO11.10)10Dlo/0
\Crlf2tm1Wjl/\Crlf2tm1Wjl
involves: 129 * BALB/c * C3H * C57BL/6
|
decreased inflammatory response |
J:107431
|
\Tg(DO11.10)10Dlo/?
\Toxtm1.1Kay/\Toxtm1.1Kay
involves: 129S/Sv * BALB/c * C3H * C57BL/6
|
arrested T cell differentiation |
J:131287
|
|
decreased T cell number |
J:131287
|
\Tg(H2-Ea-HA)HACIIAjca/0
\Tg(Tcra/Tcrb)1Vbo/0
C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo
|
abnormal articular cartilage morphology |
J:209872
|
|
abnormal CD4-positive, alpha beta T cell morphology |
J:209872
|
|
abnormal circulating cytokine level |
J:209872
|
|
abnormal lung morphology |
J:209872
|
|
autoimmune arthritis |
J:209872
|
|
heart inflammation |
J:209872
|
|
increased circulating interleukin-6 level |
J:209872
|
|
increased IgG level |
J:209872
|
|
joint inflammation |
J:209872
|
|
kidney inflammation |
J:209872
|
\Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
SJL.FVB-Tg(H2-Kb-Tcra,-Tcrb)1640Kurs
|
abnormal cytokine level |
J:149511
|
|
ataxia |
J:149511
|
|
brain inflammation |
J:149511
|
|
CNS inflammation |
J:149511
|
|
demyelination |
J:149511
|
|
increased autoantibody level |
J:149511
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:149511
|
|
increased T-helper 1 cell number |
J:149511
|
|
increased T-helper 17 cell number |
J:149511
|
|
limb paralysis |
J:149511
|
\Tg(H2KePCC)2403Stoe/?
\Tg(TcraTcrbAD10)1Hed/?
involves: C57BL/6 * SJL
|
abnormal immune tolerance |
J:92997
|
|
abnormal T cell anergy |
J:92997
|
|
decreased CD4-positive, alpha-beta T cell number |
J:92997
|
\Tg(H2KmPCC)2939Stoe/0
\Tg(Tcra2B4)1Mmd/0
\Tg(Tcrb2B4)1Mmd/0
involves: C3H/HeJ * C57BL/6 * SJL
|
abnormal T cell differentiation |
J:50143
|
|
decreased T cell proliferation |
J:50143
|
|
decreased thymocyte number |
J:50143
|
\Tg(H2KmPCC)2939Stoe/?
\Tg(TcrAND)53Hed/?
involves: C57BL/6 * SJL
|
abnormal immune tolerance |
J:92997
|
|
abnormal T cell anergy |
J:92997
|
|
decreased CD4-positive, alpha-beta T cell number |
J:92997
|
\Tg(H2KmPCC)2939Stoe/?
\Tg(TcraTcrbAD10)1Hed/?
involves: C57BL/6 * SJL
|
abnormal immune tolerance |
J:92997
|
|
abnormal T cell anergy |
J:92997
|
|
decreased CD4-positive, alpha-beta T cell number |
J:92997
|
\Tg(ILK3mHEL)3Ccg/0
\Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6JSfd * C57BL/10Sg * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
insulitis |
J:78309
|
\Tg(Ins1-Cd80)378Psoh/0
\Tg(Ins2-GP)#Psoh/0
\Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2 * FVB/N
|
absent pancreatic beta cells |
J:209714
|
|
cachexia |
J:209714
|
|
hyperglycemia |
J:209714
|
|
insulitis |
J:209714
|
|
ketosis |
J:209714
|
|
periinsulitis |
J:209714
|
|
premature death |
J:209714
|
\Tg(Ins1-Cd80)378Psoh/0
\Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2 * FVB/N
|
normal
homeostasis/metabolism phenotype |
J:209714
|
\Tg(Ins2-GP)#Psoh/0
\Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2
|
abnormal B cell selection |
J:81285
|
|
normal
homeostasis/metabolism phenotype |
J:209714
|
|
hyperglycemia |
J:81285
|
|
increased urine glucose level |
J:81285
|
\Tg(Ins2-HA)165Bri/?
\Tg(TcraCl4,TcrbCl4)1Shrm/?
involves: BALB/c * C57BL/6 * C57BL/10
|
hyperglycemia |
J:99756
|
|
insulitis |
J:99756
|
|
postnatal lethality, complete penetrance |
J:99756
|
\Tg(Ins2-HA)165Bri/0
\Tg(TcraCl4,TcrbCl4)1Shrm/0
involves: BALB/c * C57BL/6 * C57BL/10 * DBA/2
|
abnormal pancreatic islet morphology |
J:99756
|
|
hyperglycemia |
J:99756
|
|
insulitis |
J:99756
|
|
postnatal lethality |
J:99756
|
\Tg(Ins2-OVA)307Wehi/0
\Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * C57BL/6JWehi
|
autoimmune response |
J:99451
|
|
decreased pancreatic beta cell number |
J:99451
|
|
increased urine glucose level |
J:99451
|
\Tg(Ins2-TFRC/OVA)296Wehi/0
\Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:135154
|
|
increased double-positive T cell number |
J:135154
|
\Tg(KLK4mHEL)6Ccg/0
\Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
\Tg(Lck-CrmA)1Hed/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
BALB/c * C57BL/6
|
normal
immune system phenotype |
J:100451
|
\Tg(Lck-FADD)1Hed/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: BALB/c * C57BL/6J * C57L/J * DBA/2J
|
normal
immune system phenotype |
J:100451
|
\Tg(LCK-NFKBIA)5Dwb/?
\Tg(Tcra,Tcrb)1Mcd/?
involves: BALB/c * C57BL/6 * DBA/2
|
decreased interferon-gamma secretion |
J:145531
|
\Tg(Lck-Stk17b)26.1Wals/?
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * C57BL/10
|
abnormal T cell differentiation |
J:149973
|
|
decreased CD8-positive, alpha-beta T cell number |
J:149973
|
|
decreased thymocyte number |
J:149973
|
|
increased CD8-positive, alpha-beta T cell number |
J:149973
|
\Tg(LCKprBCL2)36Sjk/0
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
\Tg(ML5sHEL)5Ccg/0
\Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
\Tg(ML5sHEL)5Ccg/0
\Tg(TcrHEL3A9)1Mmd/0
\Tg(TLK2mHEL)2Ccg/0
involves: C57BL/6JSfd * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
|
thyroid gland inflammation |
J:78309
|
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?
C.Cg-Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo
|
abnormal regulatory T cell physiology |
J:112603
|
|
increased regulatory T cell number |
J:112603
|
\Tg(Pgk1-HA)1.1Vbo/?
\Tg(Tcra/Tcrb)1Vbo/?
involves: 129 * BALB/c * C57BL/6J * DBA/2J
|
decreased CD4-positive, alpha-beta T cell number |
J:125750
|
|
increased double-positive T cell number |
J:125750
|
|
increased regulatory T cell number |
J:125750
|
\Tg(Rr158-H2-Ead)1Flv/0
\Tg(Tcra1H3.1,Tcrb1H3.1)1Vire/0
involves: C57BL/6 * SJL
|
decreased double-positive T cell number |
J:124574
|
|
thymus hypoplasia |
J:124574
|
\Tg(Tcra2C,Tcrb2C)1Dlo/?
involves: C57BL/6 * SJL
|
abnormal CD8-positive, alpha beta T cell morphology |
J:125259
|
\Tg(Tcra2C,Tcrb2C)1Dlo/?
involves: C57L * DBA/2 * SJL
|
abnormal dermis papillary layer morphology |
J:95380
|
|
abnormal memory T cell physiology |
J:95380
|
|
decreased lymphocyte cell number |
J:95380
|
|
decreased thymocyte number |
J:95380
|
|
increased CD4-positive, alpha-beta T cell number |
J:95380
|
|
seborrheic dermatitis |
J:95380
|
|
thick epidermis |
J:95380
|
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T-helper 1 cell number |
J:189919
|
|
decreased interferon-gamma secretion |
J:189919
|
|
decreased interleukin-2 secretion |
J:189919
|
|
decreased interleukin-10 secretion |
J:189919
|
|
decreased T cell proliferation |
J:189919
|
|
decreased T-helper 2 cell number |
J:189919
|
|
decreased T-helper 17 cell number |
J:189919
|
|
increased interferon-gamma secretion |
J:189919
|
|
increased interleukin-6 secretion |
J:189919
|
|
increased interleukin-17 secretion |
J:189919
|
|
increased T cell apoptosis |
J:189919
|
|
increased T cell proliferation |
J:189919
|
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:83278
|
|
abnormal cytokine secretion |
J:83278
|
|
abnormal eye morphology |
J:83278
|
|
abnormal optic nerve morphology |
J:83278
|
|
axon degeneration |
J:83278
|
|
blepharitis |
J:83278
|
|
CNS inflammation |
J:83278
|
|
demyelination |
J:83278
|
|
edema |
J:83278
|
|
eyelid edema |
J:83278
|
|
increased cell proliferation |
J:83278
|
|
increased susceptibility to autoimmune disorder |
J:83278
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:83278
|
|
increased susceptibility to induced morbidity/mortality |
J:83278
|
\Tg(Tcra2D2,Tcrb2D2)1Kuch/?
involves: C57BL/6 * CD-1
|
decreased interleukin-17 secretion |
J:125296
|
\Tg(Tcra5CC7,Tcrb5CC7)IWep/0
involves: C57BL/6
|
abnormal T cell activation |
J:73608
|
\Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0
involves: C57BL/6 * DBA/2
|
abnormal positive T cell selection |
J:125548
|
\Tg(Tcra,Tcrb)3Ayr/0
involves: C57BL/6 * DBA/2
|
abnormal lymphocyte anergy |
J:80775
|
|
abnormal positive T cell selection |
J:125548
|
|
decreased T cell proliferation |
J:80775
|
\Tg(Tcra,Tcrb)24Efro/0
D1.Cg-Tg(Tcra,Tcrb)24Efro
|
abnormal cytokine secretion |
J:104243
|
|
abnormal T cell differentiation |
J:104243
|
|
autoimmune response |
J:104243
|
|
decreased T cell proliferation |
J:104243
|
|
increased autoantibody level |
J:104243
|
|
increased memory T cell number |
J:104243
|
|
increased susceptibility to autoimmune disorder |
J:104243
|
|
increased T cell proliferation |
J:104243
|
\Tg(Tcra,Tcrb)HRCAll/0
B6.Cg-Tg(Tcra,Tcrb)HRCAll
|
abnormal T cell subpopulation ratio |
J:131347
|
|
decreased CD4-positive, alpha-beta T cell number |
J:131347
|
|
decreased cytotoxic T cell cytolysis |
J:131347
|
|
decreased interferon-gamma secretion |
J:131347
|
|
increased CD8-positive, alpha-beta T cell number |
J:131347
|
\Tg(Tcra,Tcrb)HRVAll/0
B6.Cg-Tg(Tcra,Tcrb)HRVAll
|
abnormal T cell subpopulation ratio |
J:131347
|
|
decreased CD4-positive, alpha-beta T cell number |
J:131347
|
|
increased CD8-positive, alpha-beta T cell number |
J:131347
|
\Tg(Tcra,Tcrb)HRVAll/0
\Tg(TRAMP)8247Ng/0
B6.Cg-Tg(TRAMP)8247Ng Tg(Tcra,Tcrb)HRVAll
|
increased prostate gland tumor incidence |
J:131347
|
|
increased tumor incidence |
J:131347
|
|
premature death |
J:131347
|
\Tg(TcraAI4)1Dvs/0
\Tg(TcrbAI4)1Dvs/0
NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
abnormal CD4-positive, alpha beta T cell morphology |
J:93553
|
|
abnormal CD8-positive, alpha beta T cell morphology |
J:94192
|
|
abnormal cytotoxic T cell physiology |
J:94192
|
|
increased susceptibility to autoimmune diabetes |
J:94192
|
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: C57BL/6 * NOD * SJL
|
decreased dendritic cell number |
J:137009
|
|
normal
digestive/alimentary phenotype |
J:135214
|
|
normal
immune system phenotype |
J:135214
|
|
insulitis |
J:137009
|
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased susceptibility to autoimmune diabetes |
J:87251
|
|
increased activated T cell number |
J:52940
|
|
insulitis |
J:52940
|
\Tg(TcraCl1,TcrbCl1)1Shrm/0
B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm
|
abnormal fertility/fecundity |
J:106230
|
|
abnormal T cell subpopulation ratio |
J:97745
|
|
increased tumor incidence |
J:106230
|
|
weakness |
J:106230
|
\Tg(TcraCl4,TcrbCl4)1Shrm/?
B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm
|
abnormal CD8-positive, alpha-beta T cell differentiation |
J:99756
|
|
abnormal T cell subpopulation ratio |
J:99756
|
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * DBA/2J
|
abnormal cytotoxic T cell physiology |
J:66565
|
|
abnormal T cell differentiation |
J:97610
|
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6J * C57L/J * DBA/2J
|
abnormal double-negative T cell morphology |
J:79738
|
|
abnormal T cell differentiation |
J:79738,
J:90776
|
|
decreased thymocyte number |
J:79738
|
|
thymus hypoplasia |
J:79738
|
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
\Themistm1Gasc/\Themistm1Gasc
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal negative T cell selection |
J:151074
|
|
abnormal positive T cell selection |
J:151074
|
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
\Themistm1Lov/\Themistm1Lov
involves: 129 * C57BL/6 * DBA/2
|
abnormal negative T cell selection |
J:151075
|
|
abnormal positive T cell selection |
J:151075
|
|
decreased single-positive T cell number |
J:151075
|
|
increased double-positive T cell number |
J:151075
|
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
\Tnfrsf25tm1Mjo/\Tnfrsf25tm1Mjo
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:84536
|
|
abnormal thymus morphology |
J:84536
|
|
increased thymocyte number |
J:84536
|
\Tg(TcrAND)53Hed/?
involves: A/WySnSg * C57BL/6 * C57BL/10SnSg * SJL
|
abnormal positive T cell selection |
J:85777
|
|
abnormal T cell differentiation |
J:85777
|
|
abnormal T cell proliferation |
J:85777
|
|
abnormal T cell subpopulation ratio |
J:85777
|
|
abnormal thymocyte activation |
J:85777
|
|
decreased CD8-positive, alpha-beta T cell number |
J:85777
|
|
decreased double-positive T cell number |
J:85777
|
|
increased CD4-positive, alpha-beta T cell number |
J:85777
|
\Tg(TcrAND)53Hed/?
involves: C57BL/6 * SJL
|
abnormal lymph node cell ratio |
J:124701
|
|
increased CD4-positive, alpha-beta T cell number |
J:124701
|
\Tg(TcrAND)53Hed/?
\Themistm1Gasc/\Themistm1Gasc
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:151074
|
|
decreased CD4-positive, alpha-beta T cell number |
J:151074
|
|
decreased CD8-positive, alpha-beta T cell number |
J:151074
|
|
increased double-positive T cell number |
J:151074
|
\Tg(TcrAND)53Hed/?
\Themistm1Lov/\Themistm1Lov
involves: 129 * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:151075
|
|
decreased single-positive T cell number |
J:151075
|
|
increased double-positive T cell number |
J:151075
|
\Tg(TcrAND)53Hed/?
\Zbtb7btm1.1Rbo/\Zbtb7btm1.1Rbo
involves: C57BL/6 * SJL
|
abnormal T cell differentiation |
J:141145
|
\Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * NOD * SJL
|
abnormal intervertebral disk morphology |
J:36815
|
|
abnormal lymphocyte cell number |
J:36815
|
|
abnormal macrophage chemotaxis |
J:36815
|
|
abnormal metatarsal bone morphology |
J:36815
|
|
abnormal phalanx morphology |
J:36815
|
|
abnormal T cell activation |
J:36815
|
|
abnormal T cell anergy |
J:36815
|
|
abnormal T cell clonal deletion |
J:36815
|
|
abnormal T cell proliferation |
J:36815
|
|
chronic joint inflammation |
J:36815
|
|
clinodactyly |
J:36815
|
|
decreased CD4-positive, alpha-beta T cell number |
J:36815
|
|
decreased CD8-positive, alpha-beta T cell number |
J:36815
|
|
decreased joint mobility |
J:36815
|
|
enlarged spleen |
J:36815
|
|
glomerulonephritis |
J:36815
|
|
impaired neutrophil recruitment |
J:36815
|
|
increased B cell number |
J:36815
|
|
increased IgG1 level |
J:36815
|
|
kidney inflammation |
J:36815
|
|
renal glomerular immunoglobulin deposits |
J:36815
|
|
rheumatoid arthritis |
J:36815
|
\Tg(TcraTcrb)8Rest/?
C57BL/6-Tg(TcraTcrb)8Rest
|
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology |
J:85058
|
|
abnormal cytotoxic T cell physiology |
J:85058
|
|
abnormal tumor susceptibility |
J:85058
|
|
increased interferon-gamma secretion |
J:85058
|
\Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
abnormal positive T cell selection |
J:125548
|
\Tg(TcraTcrb)425Cbn/?
involves: BALB/c * C57BL/6
|
abnormal positive T cell selection |
J:87876
|
|
increased CD4-positive, alpha-beta T cell number |
J:87876
|
\Tg(TcraTcrb)425Cbn/0
involves: C57BL/6
|
abnormal cytokine level |
J:112600
|
\Tg(TcraTcrb)425Cbn/0
\Trim30atm1Yjk/\Trim30atm1Yjk
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
increased T cell proliferation |
J:215171
|
\Tg(TcraTcrb)425Cbn/0
\Trip10tm1.1Geha/\Trip10tm1.1Geha
B6.Cg-Trip10tm1.1Geha Tg(TcraTcrb)425Cbn
|
abnormal effector T cell morphology |
J:164363
|
|
decreased CD4-positive, alpha-beta T cell number |
J:164363
|
|
normal
immune system phenotype |
J:164363
|
\Tg(TcraTcrb)1100Mjb/?
either: C57BL/6 or (involves: C57BL/6 * SJL)
|
increased tumor latency |
J:134776
|
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal CD8-positive, alpha beta T cell morphology |
J:92867
|
|
abnormal cytotoxic T cell physiology |
J:92867,
J:133645
|
|
abnormal positive T cell selection |
J:92867,
J:133645
|
|
abnormal T cell clonal deletion |
J:92867
|
|
abnormal T cell subpopulation ratio |
J:92867,
J:133645
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133645
|
|
increased CD8-positive, alpha-beta T cell number |
J:92867,
J:133645
|
|
increased T cell proliferation |
J:92867
|
\Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * MRL/Mp
|
increased hepatocyte apoptosis |
J:72817
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:72817
|
|
liver inflammation |
J:72817
|
|
pale liver |
J:72817
|
\Tg(TcraTcrb)1100Mjb/?
\Themistm1Gasc/\Themistm1Gasc
involves: 129S6/SvEvTac * C57BL/6
|
abnormal positive T cell selection |
J:151074
|
|
decreased CD8-positive, alpha-beta T cell number |
J:151074
|
|
increased double-positive T cell number |
J:151074
|
\Tg(TcraTcrbNY4.1)1Pesa/0
NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa
|
increased susceptibility to autoimmune diabetes |
J:108768
|
|
insulitis |
J:108768
|
\Tg(TcraTcrbNY8.3)1Pesa/?
involves: C57BL/6 * NOD * SJL
|
increased circulating glucose level |
J:44202
|
|
pancreas inflammation |
J:44202
|
\Tg(TcraY1,TcrbY1)416Tev/0
involves: C57BL/6J * DBA/2J
|
abnormal immune tolerance |
J:84288
|
\Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:73608
|
|
abnormal interleukin secretion |
J:73608
|
|
abnormal T cell activation |
J:73608
|
|
increased T cell proliferation |
J:73608
|
\Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal double-positive T cell morphology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
abnormal thymus cell ratio |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
\Tg(TcrHEL3A9)1Mmd/0
\Tg(TLK2mHEL)2Ccg/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
|
thyroid gland inflammation |
J:78309
|
\Tg(TcrLCMV)1Aox/?
C57BL/6-Tg(TcrLCMV)1Aox
|
abnormal cytotoxic T cell physiology |
J:92228
|
|
decreased CD8-positive, alpha-beta T cell number |
J:92228
|
|
decreased double-positive T cell number |
J:92228
|
|
increased CD4-positive, alpha-beta T cell number |
J:92228
|
|
increased double-negative T cell number |
J:92228
|
|
increased IgG level |
J:92228
|
\Tg(TcrLCMV)2Aox/?
C57BL/6-Tg(TcrLCMV)2Aox
|
abnormal cytotoxic T cell physiology |
J:92228
|
|
decreased CD8-positive, alpha-beta T cell number |
J:92228
|
|
decreased double-positive T cell number |
J:92228
|
|
increased CD4-positive, alpha-beta T cell number |
J:92228
|
|
increased double-negative T cell number |
J:92228
|
\Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2
|
decreased CD8-positive, alpha-beta T cell number |
J:77696
|
|
decreased cytotoxic T cell cytolysis |
J:77696
|
|
decreased double-positive T cell number |
J:77696
|
|
decreased T cell proliferation |
J:77696
|
|
thymus hypoplasia |
J:77696
|
\Tg(TcrLCMV)327Sdz/?
involves: C57BL/6 * DBA/2J
|
abnormal T cell differentiation |
J:97610
|
|
decreased CD4-positive, alpha-beta T cell number |
J:97610
|
\Tg(TcrLCMV)327Sdz/\Tg(TcrLCMV)327Sdz
NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs
|
autoimmune response |
J:71050
|
\Tgfb1tm3.1Flv/\Tgfb1tm3.1Flv
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129 * C57BL/6 * DBA/2 * NOD * SJL
|
increased regulatory T cell number |
J:196160
|
|
increased susceptibility to autoimmune diabetes |
J:196160
|
|
increased T-helper 1 cell number |
J:196160
|
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Cd4-cre)1Cwi/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129 * C57BL/6 * DBA/2 * NOD * SJL
|
abnormal abdominal lymph node morphology |
J:196160
|
|
abnormal immune serum protein physiology |
J:196160
|
|
abnormal immune system morphology |
J:196160
|
|
abnormal immune system organ morphology |
J:196160
|
|
abnormal immune system physiology |
J:196160
|
|
abnormal interleukin secretion |
J:196160
|
|
abnormal spleen morphology |
J:196160
|
|
decreased interleukin-9 secretion |
J:196160
|
|
decreased interleukin-17 secretion |
J:196160
|
|
decreased regulatory T cell number |
J:196160
|
|
normal
immune system phenotype |
J:196160
|
|
increased interferon-gamma secretion |
J:196160
|
|
increased interleukin-2 secretion |
J:196160
|
|
increased interleukin-21 secretion |
J:196160
|
|
increased regulatory T cell number |
J:196160
|
|
increased susceptibility to autoimmune diabetes |
J:196160
|
|
normal
mortality/aging |
J:196160
|
|
pancreas inflammation |
J:196160
|
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tg(Foxp3-EGFP/cre)1cJbs/0
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129S6/SvEvTac * C57BL/6 * NOD * SJL
|
normal
immune system phenotype |
J:196160
|
|
increased regulatory T cell number |
J:196160
|
\Tgfbr2tm1.2Hlm/\Tgfbr2tm1.2Hlm
\Tnfrsf4tm2(cre)Nik/\Tnfrsf4+
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129 * C57BL/6 * NOD * SJL
|
normal
immune system phenotype |
J:196160
|
|
increased susceptibility to autoimmune diabetes |
J:196160
|
\Tigittm1Sdl/\Tigittm1Sdl
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: C57BL/6
|
decreased interleukin-10 secretion |
J:168902
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:168902
|
\Vsirtm1Lex/\Vsirtm1Lex
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S5/SvEvBrd * C57BL/6
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:222944
|
\Xcl1tm1Rakr/\Xcl1tm1Rakr
\Tg(TcraTcrb)1100Mjb/0
involves: 129/Sv * C57BL/6
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:155297
|
|
decreased cytotoxic T cell cytolysis |
J:155297
|
|
decreased interferon-gamma secretion |
J:155297
|
|
decreased T cell number |
J:155297
|
\Zap70m1Saka/\Zap70m1Saka
\Tg(DO11.10)10Dlo/0
involves: BALB/c * C3H * C57BL/6
|
decreased T cell number |
J:86607
|
|
decreased T cell proliferation |
J:86607
|
\Zap70m1Saka/\Zap70m1Saka
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: BALB/c * C57BL/6J * DBA/2J
|
abnormal positive T cell selection |
J:86607
|
|
autoimmune arthritis |
J:86607
|
\Zap70tm1.1Mmal/\Zap70tm1.1Mmal
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J
|
normal
immune system phenotype |
J:71099
|
\Zap70tm1.1Mmal/\Zap70tm1.1Mmal
\Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2
|
abnormal cytokine secretion |
J:71099
|
|
abnormal T cell proliferation |
J:71099
|
|
normal
immune system phenotype |
J:71099
|
\Zap70tm2.1Mmal/\Zap70tm2.1Mmal
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J
|
abnormal lymph node cell ratio |
J:71099
|
|
abnormal T cell morphology |
J:71099
|
|
abnormal thymus cell ratio |
J:71099
|
|
normal
immune system phenotype |
J:71099
|
\Zap70tm2.1Mmal/\Zap70tm2.1Mmal
\Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2
|
abnormal T cell morphology |
J:71099
|
|
normal
immune system phenotype |
J:71099
|
\Zap70tm2.1Weis/\Zap70tm2.1Weis
\Tg(DO11.10)10Dlo/?
involves: 129S4/SvJae * BALB/c * C3H * C57BL/6
|
abnormal positive T cell selection |
J:154166
|
\Zap70tm2.1Weis/\Zap70tm2.1Weis
\Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S4/SvJae * C57BL/6J * DBA/2J
|
abnormal positive T cell selection |
J:154166
|
|
abnormal T cell clonal deletion |
J:154166
|
Analysis Tools
Excel File